Neil P. Shah - Concepedia

Author

Neil P. Shah

University of California, San Francisco ORCID

Also Known As

Joseph Paulisin, Lee-Sherick, Alisa B., N P Shah, N Shah, N. P. Shah, N. Shah, N.P. Shah, Neil Pravin Shah, Neil P Shah, Neil P. Shah

348

Publications

14.6K

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco The University of Texas MD Anderson Cancer Center University of California, Los Angeles Bristol-Myers Squibb (United States)University of Michigan

About

Neil P. Shah is an author at University of California, San Francisco specializing in medicine, cell biology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	46	7.4K
2	Health Sciences	14	17	3.4K
3	Natural Sciences	8	8	373
4	Engineering	1	1	33
5	Biochemistry	1	1	27

Neil P. Shah

125

Publications

13.5K

Citations

H-Index

Page 1

	Year	Citations
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor Neil P. Shah, Chris Tran, Francis Y. Lee, Science Imatinib ResistanceImatinib-resistant Bcr-abl MutantsChronic Myeloid LeukemiaHematological MalignancyHealth Sciences	2004	1.8K
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz, New England Journal of Medicine	2013	1.1K
Dynamics of chronic myeloid leukaemia Franziska Michor, Timothy P. Hughes, Yoh Iwasa, Nature Hematological MalignancyTumor BiologyChronic Myeloid LeukaemiaMedicineMixed-phenotype Acute Leukemia	2005	848
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia Catherine C. Smith, Qi Wang, Chen-Shan Chin, Nature Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematology	2012	734
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz, Blood	2018	572
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Todd A. Carter, Lisa Wodicka, Neil P. Shah, Proceedings of the National Academy of Sciences	2005	554
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle Jeremy B. M. Jowett, Vicente Planelles, Betty Poon, Journal of Virology Primary ImmunodeficiencyVpr Gene ArrestsT CellsMedicineHuman Retrovirus	1995	525
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia Christine M. McMahon, Timothy T. Ferng, Jonathan Canaani, Cancer Discovery	2019	412
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology Pietro Ciceri, Susanne Müller, Alison O’Mahony, Nature Chemical Biology Molecular PharmacologyMedicinal ChemistryMedicineDual Kinase-bromodomain InhibitorsRational Drug Design	2014	347
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance Michael R. Burgess, Brian J. Skaggs, Neil P. Shah, Proceedings of the National Academy of Sciences Drug TargetMixed-phenotype Acute LeukemiaMolecular BiologyTumor BiologyMyeloid Neoplasia	2005	311

Page 1